RxDoctor Payments Data

Vera Huffnagle, MD

Neurology · Dickson, TNNPI 1700889813

Payments from drug & device makers

$4,148in general payments, 2019–2025

Across 240 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$954
  • Supernus Pharmaceuticals, Inc.$332
  • ANI Pharmaceuticals, Inc.$321
  • AbbVie$199
  • Neurocrine Biosciences, Inc.$163
  • Amgen$152
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,08999%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,148 in reported general payments places this provider in the 50th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$152,391
Medicare patients
346
Services billed
3,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$244,342
Kesimpta PenOfatumumab24$204,209
NuplazidPimavanserin Tartrate32$165,574
UbrelvyUbrogepant33$44,321
BriviactBrivaracetam36$38,141
RytaryCarbidopa/Levodopa18$22,579
Lamictal XrLamotrigine13$22,400
QuliptaAtogepant19$22,292
NuedextaDextromethorphan Hbr/Quinidine12$16,202
NamzaricMemantine Hcl/Donepezil Hcl29$13,020
Emgality PenGalcanezumab-Gnlm13$12,696
Rivastigmine61$10,029
Memantine Hcl199$8,936
Lamotrigine OdtLamotrigine35$7,853
Carbidopa-LevodopaCarbidopa/Levodopa207$7,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Dilantin$67$245,57525 claims
Acadia Pharmaceuticals IncNuplazid$91$165,57432 claims
AbbVieUbrelvy, Qulipta, Namzaric$199$79,63381 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$39$24,45034 claims
Avanir Pharmaceuticals, Inc.Nuedexta$95$16,20212 claims
Lilly USA, LLCOlanzapine$119$36615 claims
Upsher-smith Laboratories LLCTopiramate$135$34821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 361 neurology providers in Tennessee.

Other neurology in Dickson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →